Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

All chapters
Previous chapter Next chapter


mTOR, Aging and Cancer: Prospects for Pharmacological Interventions

Rapamycin is a curious drug. On the one hand it extends life and health span of genetically heterogeneous (wild type, healthy) mice when started in mid or late life; and in a dose responsive manner. Given over a lifetime, it also extends the life span of cancer prone mouse models and has positive effects in other models of age-caused diseases. On the other hand, it is routinely used long-term in (less healthy) transplant patients as an immunosuppressant to prevent allograft rejection, while a modified form (rapalog) improves immunity in the elderly. Another rapalog is effective in the long-term stabilization of disease in cancer patients. These seemingly incongruous thoughts—a drug that is supposed to suppress a major disease-defense system (including cancer) somehow extends life and health span in the lab and in cancer patients—has resulted in a certain level of cognitive dissonance regarding this drug. A black box warning that sirolimus (rapamycin) can increase the risk for cancer hasn’t helped to clarify things. What’s going on? Clearly a lot we do not understand. What is all this telling us about the systems (cell autonomous and non-autonomous) with which this drug interacts? I review progress toward the goal of clarifying the biology of this drug, and how all this fits into the general picture of preventing age-associated diseases to extend longevity; or the other way around, delaying aging to prevent age-caused maladies.

Publication details

Print publication date
01 Feb 2017
Copyright year
Print ISBN
ePub eISBN
From the book series:
Drug Discovery